Meet With...Illumina Accelerator and Illumina Ventures

Apr 10 2018https://www.eventbrite.com/e/meet-withillumina-accelerator-and-illumina-ventures...

Program Overview:
The purpose of the Meet with… Series events at JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners such as big pharma or other investment corporations, through one-on-one meetings.


On April 10th, the Director of Investments at Illumina Ventures, Wouter Meuleman, and the Head of Illumina Accelerator, Amanda Cashin, will give an overview presentation about each group's key areas of interest including the types of early-stage companies they look for. Following the presentation, you'll have the opportunity to introduce yourself to Wouter and Amanda during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Illumina Ventures (Series A-stage), Illumina Accelerator (Seed-stage), or Illumina, Inc. will be scheduled, providing an intimate forum to discuss your company.

Some areas of interest include:

  • Genomics Research and Tools
  • Therapeutics Companies and Discovery Platforms (e.g., Oncology)
  • Reproductive Health
  • Agrigenomics
  • Applied Genomics
  • Complex Diseases
  • Microbial Genomics and Microbiome
  • Informatics, Genomics Analysis

Illumina Ventures invests in early-stage companies that are pioneering new applications of genomics and enabling precision medicine – including life science tools, clinical diagnostics, and therapeutic platforms. Their limited partners include Illumina, the world's leading genomics solutions provider, and global corporate, institutional, sovereign, and individual investors. The fund's team members have spent decades at the forefront of genomics innovation and share a passion for improving human health. For more information, visit http://www.illuminaventures.com.

Illumina Accelerator is the world's first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. It provides select startups with seed investment, business guidance, access to Illumina's sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area during each six-month funding cycle. For more information, visit http://www.illumina.com/accelerator.

Illumina, Inc., is looking for potential partnerships with companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal wellness. Their goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. For more information, visit http://www.illumina.com.


Speakers:
Amanda Cashin, Ph.D. | Head of Illumina Accelerator, Illumina read bio»
Wouter Meuleman, Ph.D. | Director of Investments, Illumina Ventures read bio»


Agenda:
10:30am | Registration & Networking
11:00am | Company Presentation and Q&A
11:45am | Lunch & Networking
12:45-5:00pm | One-on-one Meetings*

*Companies must have applied ahead of time and be approved for a one-on-one meeting. Application period ends March, 12, 2018. Apply Here.

 

Representative:

Amanda Cashin, Ph.D. | Head of Illumina Accelerator, Illumina
Amanda Cashin, Ph.D. is Co-Founder and Head of Illumina Accelerator, a leading company creation engine and investment vehicle focused on building genomics-driven startups. Founded in Fall 2014 in San Francisco, Illumina Accelerator is investing in emerging startups, advancing breakthrough applications in genomics, including applications in therapeutics, women's health, cancer diagnostics, consumer nutrition, agriculture, synthetic biology, and skin microbiome.

Previously, Amanda was Senior Vice President of Alexandria Venture Investments/Alexandria Real Estate Equities, Inc. In her role, she helped lead Alexandria Venture Investments, which has over $250 million in capital deployed and committed to breakthrough life science and technology companies and leading venture capital funds. Amanda also led a team of life science professionals with strong science and business expertise responsible for industry research, company analysis, business development, and thought leadership limitations to help position Alexandria at the forefront of the industry.

She earned a Ph.D. in Chemical Biology from the California Institute of Technology and graduated summa cum laude with a Bachelor's degree in Physical Organic Chemistry from the University of Colorado, Boulder. Her scientific expertise and peer-reviewed publications are in the fields of biochemistry, organic chemistry, physical chemistry, pharmacology, electrophysiology, and neuroscience.
Connect with Amanda: Connect on LinkedIn


Wouter Meuleman, Ph.D. | Director of Investments, Illumina Ventures
Wouter is Director of Investments at San Francisco-based Illumina Ventures. Prior to Illumina Ventures, Wouter worked at Illumina, Inc. in various roles throughout the organization including R&D, Product Development, and Corporate Development. A physical chemist by training, he began his career in life sciences as first hire for Oxford University spin-out Oxamer, a company founded in 2003 by Prof. Sir Edwin Southern, where he led the development a benchtop DNA microarray fabrication platform. Following the company's incorporation into Oxford Gene Technology in 2005, he continued working alongside Prof. Southern leading R&D programs in areas such as single cell gene expression analysis and novel applications for DNA microarrays. He obtained his undergraduate and Master's degree in Chemistry from the University of Ghent, Belgium; a PhD in Chemical Engineering from the University of Newcastle, U.K; and an MBA from the University of Cambridge, U.K.

Connect with Wouter: Connect on LinkedIn


Fees:
Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 10th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 12, 2018. Your application will be reviewed and you will be notified of acceptance by March 23, 2018. Acceptance of one-on-one meeting is not guaranteed as all applications must be approved


About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.


Venue:
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It



Share